Cort, I dont get it? Did they "dis" you?
For eg. how does a retrovirus contribute towards the difficulty swallowing and the need for tube feeding that some severe ME patients are experiencing? (Does this happen with HIV I wonder?)
What is causing the powerful headaches, light and sound intolerance and in some cases intolerance to touch? (Do AIDS patients experience light, sound, touch sensitivity I wonder?)
this is so freaking exciting! as filfla4 just posted above, we will be able to watch the closing plenary LIVE!!!!!!!!!!!!!!!!!!
(Q&A will be a live webcast. http://videocast.nih.gov/summary.asp?live=9582)
and apparently it is not just the closing plenary that will (eventually) be made available via webcast. i got this from diana, the conference's logistics coordinator:
Thank you for your e-mail. We were awaiting the webcast link, which is
http://videocast.nih.gov. This link can now also be found on the xmrv
webpage under 'registration' and under ' program'.
Presentations will be placed on our website only after explicit consent
of the speakers within 2-3 weeks after the workshop.
Best wishes,
Diana
It starts out with basic stuff; where the virus integrates itself into the cell's genome, which types of mice may contain XMRV-like sequences, and then there is a presentation on a 'novel gene product' of XMRV - which means? what - a protein?? In any case it appears to be something new to science which is always interesting.
In the next session there is a talk on animal 'models', which are animals researchers use to give XMRV to and then study. Animal models are critically important to understanding how pathogens function and its good to see researchers focusing on animal models so early. Dr Bishop will talk on 'Host Restriction Factors' which are factors in our cells that restrict viral replication. These factors may be one reason why XMRV appears to be different in prostate cancer tissues and the blood. Next comes a VERY INTERESTING lecture.
Dr. Villinger then talks on why XMRV Induces a Chronic Replicative Infection in Rhesus Macque Tissues and But Not in the Blood". We've been wondering where, if any place, XMRV is replicating? We know it hardly happens in the blood but is there a tissue somewhere (besides the prostate) where it's growing away? Dr. Villinger will tell us where in the bodies of these macaques XMRV has found a home. Is it the nervous system? (Wouldn't THAT be exciting/appalling...) How about the lymph nodes? The blood vessels? These are macaques, not humans, but this presentation could have profound implications.
The next talk by Dr. Kazak will fit in perfectly here because he will look at different variants in the XPRI receptor that XMRV uses to enter cells. These variants may determine which cells XMRV can get into and cannot. The next day starts out with the prostate cancer series which we will bypass, except to say that Dr. Singh is giving a lecture on pathogenesis. The section on CFS comes next.
Dr. Mikovits and Dr. Ruscetti chair the section and he (not Dr. Mikovits) will lead off with a talk on subject he was hardly aware of until two years ago - chronic fatigue syndrome. Dr. Hanson is next. Thus far she has the only CFS/XMRV NIH grant that has been funded. It's a full ROI grant which means (a) that she must have had some preliminary data and (b) that data must have been positive - so here we appear to have the third positive XMRV study to appear. We know she is studying Dr. Bell's pediatric patients (or formerly 'pediatric' now middle-aged patients) and that her rather complex study wll look at a variety of immunological and other features. One interesting question will be if she has blood samples from 25 years ago from these patients.
Right next to her Dr. Huber will presumably report on her negative study - an interesting juxtaposition indeed. Dr. Lo will report on the Alter/Lo positive finding and then we believe we'll have a second positive study report by none other than Dr. Mikovits herself. This appears to be the Invest in ME/WPI UK study that used an independent lab to replicate the WPI's results. The title of this one is intriguing "the Detection of Infectious XMRV in the blood of ....in the UK". One wonders if the inclusion of the word "infectious' in there could mean anything special about this study?
The Assay development section will start off by a lecture by a man who's never been able to find any XMRV in patient's blood - Dr. Switzer of the CDC. After the Alter/Lo study and the FDA's statement that 'sample preparation' could've played a role in the inability of the CDC to find XMRV this lecture could be interesting. (Dr. Vernon's test tube comments come to mind)... Could Dr. Switzer tell us something surprising here? aka 'we made a mistake?'.
Dr. Bagni will represent the WPI as she explains how to produce an antibody test for XMRV then we'll get good news about the development of XMRV immunoassays for large scale population studies. Finally Dr. Kearney - who may be part of the Blood Working Group will talk on his success in finding XMRV in blood products. (Things are definitely moving forward on the diagnostic front.)
In the last session on Epidemiology the Bannert lecture will indicate to us that he did not find XMRV but he also shows that the bug can infect blood cells - which sounds that he's replicated a key part of the Science paper (!) but still can't find the virus...We'll have another opportunity for another positive study when Dr. Blomberg talks about his search for XMRV in Sweden. Finally it appears that another member of the Blood Working Group will report multi-laboratory evaluations of different XMRV assays.
Dr. De Meirleir is believed to have a poster providing the results of another postive study and the identification of an immmunological signature associated with XMRV infection. At this point it appears there may be at least three positive studies and possibly four.
The 2-day Workshop indicates that Science is marching forward very quickly; indeed at lightspeed compared to what we are used to. If XMRV wins out this could be just the beginning; the medical research establishment (contrary to our experience) in the US, after all, is vast indeed. Months ago, Dr. Klimas reported that retrovirologists were hungry for something new...Might ME/CFS go from doormat to hot research ticket? That would be something indeed.
this is so freaking exciting! as filfla4 just posted above, we will be able to watch the closing plenary LIVE!!!!!!!!!!!!!!!!!!
(Q&A will be a live webcast. http://videocast.nih.gov/summary.asp?live=9582)
and apparently it is not just the closing plenary that will (eventually) be made available via webcast. i got this from diana, the conference's logistics coordinator:
Thank you for your e-mail. We were awaiting the webcast link, which is
http://videocast.nih.gov. This link can now also be found on the xmrv
webpage under 'registration' and under ' program'.
Presentations will be placed on our website only after explicit consent
of the speakers within 2-3 weeks after the workshop.
Best wishes,
Diana
The title of this one is intriguing "the Detection of Infectious XMRV in the blood of ....in the UK". One wonders if the inclusion of the word "infectious' in there could mean anything special about this study?
What time will that be EST?
and then we believe we'll have a second positive study report by none other than Dr. Mikovits herself. This appears to be the Invest in ME/WPI UK study that used an independent lab to replicate the WPI's results. The title of this one is intriguing "the Detection of Infectious XMRV in the blood of ....in the UK". One wonders if the inclusion of the word "infectious' in there could mean anything special about this study?
I tossed this out before, but I hope someone in CFIDS/ME/{other subgroup} activist circles is keeping in mind that research on one or more virii and research on how to cure us may not be the same thing. Whatever's wrong could have set off a dysfunction which doesn't resolve itself if the pathogen circulating in blood can be controlled, or even if the pathogen hiding in some organs can be flushed out. It could be that the state of a complex system is disrupted and become stable in the new, malfunctioning state. e.g. : virus could be treated, but an autoimmune disease remains. It can still be cured, but it requires a deeper insight into how and why it is broken.
the immunological signature is comparable to that of a patient with AIDS.
@cort: from your buzz:
mikovits did include the word infectious already in the science addendum :
Detection of an infectious retrovirus, XMRV, in blood cells of patients
with chronic fatigue syndrome
http://www.landesbioscience.com/journals/virulence/article/MikovitisVIRU1-5.pdf
so why would it this time mean anything special?
there could be new things in this new study but the title doesnt tell us because same title style was used in addendum also
I'm really looking forward to hearing about Professor De Meirleirs work, sound like he has proven causality!?
Didn't know that....When I looked at the titles of the other presentations nobody mentioned infectious - it stood out for me.
Cort said:Dr. Mikovits stated she's found a signature as well. If they are right then that's a BIG step for XMRV